MyMD Pharmaceuticals, Inc. Stock Price, News & Analysis

TNF Pharmaceuticals (NASDAQ: TNFA) announced significant positive topline results from a Phase 2a study of MYMD-1® (isomyosamine) for sarcopenia treatment. The double-blind, placebo-controlled study in patients aged 65+ showed significant decreases in inflammatory biomarkers, including TNF-α (P=0.008), IL-6 (P=0.03), and sTNFR1 (P=0.02), with no serious adverse events reported.

Based on these results, the company plans to initiate a Phase 2b study in early 2025. The global TNF inhibitor market is valued at $39.7 billion in 2024, expected to reach $47.3 billion by 2029. The sarcopenia treatment market, currently at $3.07 billion, is projected to grow to $4.02 billion by 2029, with over 50 million people affected globally.

TNF Pharmaceuticals (Nasdaq: TNFA) is advancing its lead program, MYMD-1®, through fully funded mid-stage clinical trials. MYMD-1 is a small molecule that blocks excessive TNF-alpha activity to regulate the immuno-metabolic system. The company's next clinical studies will focus on sarcopenia/frailty following statistically significant results from a Phase 2 study.

MYMD-1 met primary endpoints in reducing chronic inflammatory markers with statistical significance in sarcopenia/frailty. The company also holds FDA-cleared Phase 2 INDs for MYMD-1 in rheumatoid arthritis and Hashimoto's thyroiditis. TNFA is preparing to reveal its next steps towards value creation and long-term growth.

TNF Pharmaceuticals, formerly MyMD Pharmaceuticals, has begun trading under its new Nasdaq stock symbol TNFA as of July 24, 2024. This change reflects the company's focus on inhibiting TNF-alpha to regulate the immuno-metabolic system. The company's lead clinical candidate, MYMD-1, blocks excess TNF-α activity, potentially restoring immune system control and regulation.

Dr. Mitchell Glass, President and Chief Medical Officer, emphasized that this rebranding aligns with their core science and highlights MYMD-1's potential as the first TNF-α inhibitor in its indication. The company's CUSIP remains unchanged, and current stockholders need not take any action regarding the symbol change.

TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals) announced a corporate rebranding, effective July 22, 2024. The company's stock will trade under the new symbol "TNFA" on Nasdaq starting July 24, 2024. This change aligns with their focus on TNF-alpha inhibition for immuno-metabolic regulation.

Their lead candidate, MYMD-1®, is an oral TNF-alpha inhibitor targeting multiple immune-metabolic disorders. Following a successful Phase 2 study in sarcopenia completed in 2023, the company plans to advance to mid-stage clinical trials. MYMD-1 distinguishes itself from current TNF-α blockers by offering oral administration, potentially transforming treatment for autoimmune and inflammatory diseases, including age-related conditions.

MyMD Pharmaceuticals announces the appointment of Mitchell Glass, M.D., as its new president and chief medical officer. Dr. Glass brings a 35-year career in life sciences, with notable drug approvals and extensive regulatory experience. His expertise is expected to guide MyMD through mid-stage clinical trials, particularly focusing on MYMD-1, a TNF-α inhibitor. In addition, Stephen Friscia, an experienced investment strategist, joins the board. These appointments aim to strengthen MyMD's leadership as it advances its clinical programs for age-related and autoimmune diseases.

MyMD Pharmaceuticals has secured up to $42 million in strategic investments through two private placement funding rounds. The first round raised $7 million from PharmaCyte Biotech, while the second round secured another $7 million from existing shareholders. These financings involve Series G and Series F-1 Preferred Stock, both convertible to MYMD common stock, with accompanying warrants. The closings are anticipated around May 22, 2024. The Series G Preferred Stock includes 7,000 shares with a $1,000 per share value, and Series F-1 includes 5,050 shares. The funds are expected to support MyMD's clinical studies on MYMD-1 for sarcopenia over the next two years. The full conversion and warrant exercise are subject to stockholder approval.

PharmaCyte Biotech has announced a $7 million strategic investment in MyMD Pharmaceuticals, a company focused on treating inflammatory diseases, age-related conditions, and autoimmune disorders. This investment is part of PharmaCyte's strategy to leverage its $65 million cash position to enhance stockholder value. MyMD's lead product, MYMD-1, has shown promising results in a Phase 2 clinical trial for sarcopenia, and the company plans to move forward with further clinical studies in collaboration with the FDA. Both companies express optimism about the potential for future collaboration and the benefits of combining their expertise and resources.